Scholarlink

<p>We report an extremely rare case of <i>GP2-NTRK1</i> fusion-positive pancreatic ductal adenocarcinoma (PDAC) with liver metastases in a 78 year-old woman. PDAC is an aggressive cancer that presents with locally advanced or metastatic disease in more than 50% of patients at the time of diagnosis. This is the first case of <i>GP2-NTRK1</i> fusion-positive PDAC that was successfully treated with gemcitabine and nab-paclitaxel followed by entrectinib and larotrectinib, which resulted in long-term survival of more than 54 months from diagnosis and 34 months from initiation of TRK inhibitor therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long-term disease control of GP2-NTRK1 fusion-positive pancreatic adenocarcinoma with liver metastases using sequential tyrosine receptor kinase inhibitors

  • 期刊论文

  • 发表日期：

    2026年7月7日

查看全文
  • Sho Tazuma,
  • Takeshi Sudo,
  • Kenta Baba,
  • Takashi Onoe,
  • Tatsuaki Sumiyoshi,
  • Kazuya Kuraoka,
  • Kenichiro Uemura,
  • Shinya Takahashi,
  • Hirotaka Tashiro,
  • Yosuke Shimizu

摘要

We report an extremely rare case of GP2-NTRK1 fusion-positive pancreatic ductal adenocarcinoma (PDAC) with liver metastases in a 78 year-old woman. PDAC is an aggressive cancer that presents with locally advanced or metastatic disease in more than 50% of patients at the time of diagnosis. This is the first case of GP2-NTRK1 fusion-positive PDAC that was successfully treated with gemcitabine and nab-paclitaxel followed by entrectinib and larotrectinib, which resulted in long-term survival of more than 54 months from diagnosis and 34 months from initiation of TRK inhibitor therapy.